Response Biomedical Corp. Schedules Fourth Quarter and Fiscal Year 2012
Earnings Release and Announces Conference Call
VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 03/06/13 -- Response
Biomedical Corp. ("Response") (TSX:RBM)(OTCBB:RPBIF) will release its
fourth quarter and fiscal year 2012 financial results after the
markets close on, March 11, 2013.
Jeffrey L. Purvin, Chief Executive Officer, will host a conference
call to discuss the fourth quarter and fiscal year 2012 financial
results on March 11, 2013 at 2:00 p.m. PST (5:00 p.m. EST), shortly
after the initial release. Also participating in the call will be
Bill Adams, Chief Financial Officer.
The conference call will be webcast live and is also available by
dialing 1-877-643-7155 in North America or 1-914-495-8552 for all
other locations. The conference ID number is 18510597 and
participants are encouraged to initiate their calls at least 10
minutes in advance of the 2:00 p.m. PDT (5:00 p.m. EDT) start time to
ensure a timely connection.
The live webcast and earnings release will be accessible from:
Response Biomedical - Investors - Presentations
(http://responsebio.com/investors/presentations). A replay of the
conference call will also be available online approximately two hours
after the call and for 90 days thereafter.
About Response Biomedical Corp.
Response develops, manufactures and markets rapid on-site diagnostic
tests for use with its RAMP(R) Platform for clinical, biodefense and
environmental applications. RAMP(R) represents a unique paradigm in
diagnostics that provides reliable laboratory quality results in
minutes. The RAMP(R) Platform consists of a reader and single-use
disposable test cartridges and has the potential to be adapted to
more than 250 medical and non-medical tests currently performed in
laboratories. Response clinical tests are commercially available for
the early detection of heart attack, congestive heart failure, Flu A
+ B and RSV. In the non-clinical market, RAMP(R) tests are currently
available for the environmental detection of West Nile Virus and for
Biodefense applications including the rapid on-site detection of
anthrax, smallpox, ricin and botulinum toxin.
Response is a publicly traded company listed on the TSX under the
trading symbol "RBM" and quoted on the OTC Bulletin Board under the
symbol "RPBIF". For further information, please visit the Company's
website at www.responsebio.com.
Certain statements contained in this news release constitute
forward-looking information or forward-looking statements
(collectively, "forward-looking statements") with the meaning of
applicable securities legislation. Forward-looking statements are
typically identified by words such as "believe", "may", "will",
"project", "anticipate", "continue", "estimate", "expect", "intend"
and other similar words suggesting future events or future
performance. Forward-looking statements are made based on assumptions
made by the Company regarding various matters. Although the Company
believes the expectations reflected in such forward-looking
statements, and the assumptions upon which such forward-looking
statements are made, are reasonable, there can be no assurance that
such expectations will prove to be correct.
Readers are cautioned not to place undue reliance on forward-looking
statements included in this news release, as there can be no
assurance that the plans, intentions or expectations upon which the
forward-looking statements are based will occur. Such forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause the Company's actual results, events or
developments to be materially different from any future results,
events or developments expressed or implied by such forward-looking
statements. Many factors may cause the Company's actual results to
differ materially from any forward-looking statement, including the
factors detailed in the Company's filings with the Securities and
Exchange Commission and Canadian Securities regulatory authorities,
including but not limited to our amended annual report on Form 10-K,
our quarterly reports on Form 10-Q, our Annual Information Form and
other filings with the Securities and Exchange Commission and
Canadian securities regulatory authorities.
The forward-looking statements contained in this news release are
current as of the date hereof and are qualified in their entirety by
this cautionary statement. Except as expressly required by applicable
securities laws, the Company does not undertake any obligation to
publicly update any forward-looking statements, whether as a result
of new information, future events or otherwise.
Response Biomedical Corp.
VP, Administration & Corporate Communications
Press spacebar to pause and continue. Press esc to stop.